NCT00091689View on ClinicalTrials.gov

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Melanoma
Interventions
DRUG

852A

Trial Locations (2)

Unknown

Dartmouth-Hitchcock Medical Center, Lebanon

Oklahoma Medical Research Foundation, Oklahoma City

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY